| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, May 2001, p. 2262-2272, Vol. 80, No. 5

and
*Department of Chemical Engineering, University of California,
Santa Barbara, California 93106;
Department of Chemistry,
University of Chicago, Chicago, Illinois 60637; and
Department of Pediatrics, University of California, Los
Angeles, California 90059 USA
| |
ABSTRACT |
|---|
|
|
|---|
Langmuir isotherms and fluorescence and atomic force microscopy images of synthetic model lung surfactants were used to determine the influence of palmitic acid and synthetic peptides based on the surfactant-specific proteins SP-B and SP-C on the morphology and function of surfactant monolayers. Lung surfactant-specific protein SP-C and peptides based on SP-C eliminate the loss to the subphase of unsaturated lipids necessary for good adsorption and respreading by inducing a transition between monolayers and multilayers within the fluid phase domains of the monolayer. The morphology and thickness of the multilayer phase depends on the lipid composition of the monolayer and the concentration of SP-C or SP-C peptide. Lung surfactant protein SP-B and peptides based on SP-B induce a reversible folding transition at monolayer collapse that allows all components of surfactant to be retained at the interface during respreading. Supplementing Survanta, a clinically used replacement lung surfactant, with a peptide based on the first 25 amino acids of SP-B also induces a similar folding transition at monolayer collapse. Palmitic acid makes the monolayer rigid at low surface tension and fluid at high surface tension and modifies SP-C function. Identifying the function of lung surfactant proteins and lipids is essential to the rational design of replacement surfactants for treatment of respiratory distress syndrome.
| |
INTRODUCTION |
|---|
|
|
|---|
Treating premature infants with
respiratory distress syndrome with replacement surfactants derived from
natural and synthetic sources has significantly reduced neonatal
mortality (Robertson and Halliday, 1998
). Native surfactant is complex,
and includes multiple lipid species and four specific proteins (SP-A,
-B, -C, and -D). In fact, the lipid and protein composition of native surfactant is quite different even between cows and pigs, the sources
of most animal-based replacement surfactants (Bernhard et al., 2000
).
The composition variations among different clinically used replacement
surfactants are even greater and depend both on the nature of
extraction from the animal sources and the choice of "additives"
(Bernhard et al., 2000
). However, a fairly limited number of components
are generally agreed to be essential to surfactant performance in vivo
and simplify the choices for model systems for study (Robertson and
Halliday, 1998
; Goerke, 1998
). These include saturated
dipalmitoylphosphatidylcholine (DPPC), unsaturated phosphatidylcholines
and phosphatidylglycerols (PG) (Veldhuizen et al., 1998
), and the two
amphiphilic surfactant-specific proteins, SP-B (Hawgood et al., 1998
)
and SP-C (Johansson, 1998
). Palmitic acid (PA), while found at low
concentrations in native surfactants (Veldhuizen et al., 1998
), is a
common additive to replacements surfactants such as Survanta
(Bernhard et al., 2000
). However, the function of PA in the monolayer
in native or replacement surfactants is not well understood.
Proper pulmonary function requires low surface tensions during
expiration to minimize the work of breathing (Schürch et al., 1976
). This would seem to require that lung surfactant form rigid monolayers capable of low surface tension on compression. However, lung
surfactant monolayers also must be fluid enough to spread rapidly
during the expansion of the interface that accompanies inspiration
(Bastacky et al., 1995
). Although the individual components of lung
surfactant are either good at lowering surface tension (DPPC,
especially when mixed with PA) or fluidizing the monolayer (unsaturated
PG and PC, proteins), no single lipid or protein exhibits
both properties.
DPPC forms a semi-crystalline monolayer capable of surface
tensions near zero when fully compressed. However, DPPC fails as a lung
surfactant (Poulain and Clements, 1995
; Robertson and Halliday, 1998
)
as it is slow to adsorb from aqueous suspension and respreads slowly
when compression is relieved. This help explains the significant fraction of unsaturated phospholipids and hydrophobic proteins in
native surfactant (Veldhuizen et al., 1998
; Hawgood et al., 1998
;
Johansson, 1998
). Although unsaturated lipids and proteins facilitate
surfactant adsorption and spreading, they collapse at relatively high
surface tensions via the ejection of material from the monolayer
(Tchoreloff et al., 1991
; Lipp, 1997
; Lipp et al., 1998
; Schürch
et al., 1976
; Nag et al., 1998
). The ejected material does not readily
reincorporate into the monolayer on expansion (Lipp et al., 1998
) (see
Fig. 2).
The contradictory requirements of lung surfactant monolayers
have led to the "squeeze-out" theory of lung surfactant function: the unsaturated lipids and proteins in lung surfactant are selectively removed or "squeezed-out" from the monolayer during compression, leading to a DPPC-enriched monolayer capable of low surface tension. However, in vitro studies of captive (Schürch et al., 1998
;
Ingenito et al., 1999
) and pulsating (Krueger and Gaver, 1999
) air
bubbles in contact with aqueous surfactant show that the necessary mass transfer to the interface requires that the surfactant remain within a
few nanometers of the interface. Hence, current thought is that the
lipids and proteins "squeezed-out" from the monolayer occupy a
"surface associated reservoir" near the interface (Schürch et
al., 1998
). In vivo, electron microscopy has shown areas within alveoli
that have discontinuous multilayer patches along with continuous
monolayers (Bastacky et al., 1995
; Schürch et al., 1998
;
Tchoreloff et al., 1991
).
Langmuir monolayers at the air-water interface provide experimentally
useful model systems for studies of lung surfactants and other
amphiphilic molecules. Care is necessary to extrapolate Langmuir
monolayer behavior to lung surfactant behavior in vivo, but general
correlations between in vitro and in vivo behavior are starting to
emerge (Bernhard et al., 2000
; Cochrane and Revak, 1991
; Goerke, 1998
;
Jobe, 1998
; Lipp et al., 1996
, 1998
). The phase behavior of surfactants
in two dimensions is determined by pressure-area isotherms. Additional
information about the morphology of the monolayer domains is accessible
by modern visualization techniques such as fluorescence and atomic
force microscopy. We present isotherms, fluorescence microscopy, and
atomic force microscopy to show that the lung surfactant-specific
proteins SP-B and SP-C and peptides based on these proteins interact
with the various lipid species to create localized
monolayer-to-multilayer transitions that provide low surface tensions
on compression and rapid and repeatable respreading on expansion. These
lipid- and protein-induced transitions are modified by changes in the
monolayer mechanical properties induced by the addition of palmitic
acid to DPPC/POPG (palmitoyloleoylphosphatidylglycerol) monolayers. The
net result of these interactions is that all of the lipid and protein
components of lung surfactant remain at the interface (or at least
within Schürch's "surface associated reservoir"
(Schürch et al., 1998
)) during the entire compression and
expansion cycle; removal of a significant fraction of the unsaturated
and protein components of the monolayer, that is, classical
"squeeze-out," is not required for low surface tensions.
Identifying the roles of the individual lipid and protein species in
lung surfactants is essential to more rational design of replacement
lung surfactants for treatment of respiratory distress syndrome.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Protein synthesis
Surfactant protein B is a 78-residue, lipid-associating protein
found in mammalian lung surfactant (Hawgood et al., 1998
). Each monomer
has disulfide links at the mid-sequence, N-terminal, and C-terminal
sections, suggesting the main chain may assume a hairpin-like format.
The native SP-B protein has a net positive charge of 8 (10 cationic and
2 anionic residues), a large fraction of strongly hydrophobic residues,
and has four amphipathic helical segments with the helical axes
oriented parallel to the interface (Gordon et al., 1996
, 2000
).
Preparations from native material are generally homodimeric.
The full-length human 78-amino acid sequence of surfactant protein
(SP-B1-78) is shown below. In each sequence, the charged residues are indicated with a "+" or a "
" sign:
|
To simplify synthesis and to try to isolate the essential
features of SP-B, a peptide based on the N-terminus of SP-B known as
SP-B1-25 was synthesized (Bruni et al., 1991
).
SP-B1-25 is able to recreate many of the
functions of the full-length SP-B protein both in vivo and in vitro
(Lipp et al., 1996
, 1998
; Longo et al., 1993
). Both full-length SP-B
and SP-B1-25 form amphipathic
-helices
(Gordon et al., 1996
, 2000
) that help orient the protein at the
interface. The amino acid sequence of SP-B1-25
is as follows:
|
-helical conformation between residues 9 and 34 (Johansson, 1998
|
(SP-C) |
-helix is
~3.7 nm and orients along the acyl chains of lipids in a monolayer or
bilayer environment (Gericke et al., 1997
|
(SP-Cff) |
Peptide synthesis reagents including Fmoc amino acids and coupling solvents were obtained from Applied Biosystems (Foster City, CA). All organic solvents used for sample synthesis, purification and preparation were HPLC grade or better from Aldrich Chemical Co. (Milwaukee, WI). The full-length and peptide versions of SP-B were synthesized by the solid-phase method of Merrifield, with the use of a tert-butyloxycarbonyl strategy or by Fmoc strategies (UCLA Peptide Synthesis Facility). The crude peptides were purified by C4-column (Vydac, Hesperia, CA) reversed-phase high-performance liquid chromatography (HPLC) with a mixture of water, acetonitrile, and 0.1% trifluoroacetic acid. Solvents from HPLC and ion-pairing agents were removed from the purified peptides by vacuum centrifugation, and the expected molecular mass of the peptide was obtained by fast atom bombardment mass spectrometry or electrospray mass spectroscopy (UCLA Center for Molecular and Medical Sciences Mass Spectrometry). Quantitative amino acid composition for the peptide was determined at the UCLA Protein Microsequencing Facility.
SP-Cff was synthesized on a 0.25 mmol scale using an Applied Biosystems 431A peptide synthesizer using FastMoc chemistry. The peptide was synthesized using a prederivatized Fmoc-leu-PEG-PS resin (PerSeptive Biosystems, Farmington, MA) having a substitution of 0.18 mmol/g. Residues Gly-33 to Gly-29 were single-coupled, while the remaining sequence was double-coupled to the N-terminus. Cleavage and deprotection of the peptide-resin was carried out in a 10-ml TFA, 0.25-ml ethanedithiol, 0.5-ml thioanisole, and 0.5-ml water mixture for 1.5 h. The reaction mixture was then removed by vacuum filtration through a medium porosity fritted glass funnel and the resin washed sequentially with 1 ml TFA, then 5 ml DCM, and finally with 5 ml of isopropanol/TFA (95:5, v/v) to ensure separation of the peptide from the resin.
The crude peptide was purified by reverse-phase HPLC with a Vydac C4
column (1 cm × 20 cm; The Separations Group, Hesperia, CA) using
a water-acetonitrile/isopropanol (1:1, v/v) linear gradient with 0.1%
TFA as an ion-pairing agent. The molecular weight of the full length
SP-Cff was confirmed by MALDI-TOF mass spectrometry using a
Voyager RP-RBT2 reflection time of flight mass spectrometer (PerSeptive
Biosystems, Inc., Framingham, MA).
-Cyano-4-hydroxycinnamic acid was
used as a matrix and bovine insulin was used as an internal calibration standard.
Preparation of model monolayers
Model monolayers were spread from organic solvents by mixing the
proteins or peptides with the appropriate amounts of saturated DPPC,
unsaturated POPG, and PA (all from Avanti Polar Lipids, Inc.,
Alabaster, AL; 99% purity) in the weight ratios of 68:22:8 in
3:1 chloroform/methanol (Fisher Spectranalyzed). This lipid mixture is
a close functional mimic to natural lung surfactants both in vitro and
in vivo (Tanaka et al., 1986
). However, the composition of native
surfactant varies significantly from species to species, and the
compositions of replacement surfactants vary even more due to
difficulties in extraction and in the number and type of additives
used, so there is no universally accepted surfactant composition as yet
(Bernhard et al., 2000
; Mizuno et al., 1995
). The fluorescent probe
1-palmitoyl, 6-(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl-)-PG (NBD-PG, Molecular Probes, Eugene, OR) was added at lipid mole ratios of 0.5 to 1%. The fluorescent probe segregates to disordered or
fluid phases, which then appear bright in images; the probe is absent
from the solid or liquid condensed phases, which appear black or dark
(Knobler and Desai, 1992
).
Survanta was purchased from Ross Laboratories (Columbus, OH). Survanta is natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and the surfactant-associated proteins SP-B and SP-C, to which DPPC, PA, and tripalmitin are added to standardize the composition. The approximate composition is 25 mg/ml phospholipid (of which ~50-60% is DPPC), 0.5-1.75 mg/ml triglycerides, 1.5-3.5 mg/ml free fatty acids. Survanta contains both native SP-B and SP-C, but in concentrations less than that of native surfactant due to losses during the extraction process. For these experiments, the lipids and proteins were diluted in 0.9% sodium chloride solution at a total concentration of ~2 mg/ml. For fluorescence experiments, NBD-PG was added to the Survanta by suspending the dye in the same sodium chloride solution, then adding a small percentage (0.5 wt %) to the Survanta solution by gentle swirling. Additional SP-B peptide was added by the same procedure. The Survanta suspension was spread at the interface by depositing small drops of the aqueous suspension onto the subphase surface.
All other monolayers were spread from a 3:1 chloroform/methanol
spreading solution at typical concentrations of 0.5-1 mg/ml onto a 150 mM NaCl, 5 mM CaCl, 0.2 mM NaHCO3, pH 6.9 subphase in a temperature-controlled microfluorescence film balance
(Lipp et al., 1997a
; Lipp, 1997
). The trough is milled from a solid piece of Teflon with a working surface area of ~120
cm2 and a subphase volume of ~150 ml. A single
Teflon barrier runs linearly along the top edge of the trough and is
driven by a motorized translation stage. The barrier is spring-loaded
against the trough and the ends of the barrier in contact with the well
edges are beveled at an angle of ~10° to minimize leakage of
surfactant. Temperature control of the subphase is achieved through the
use of nine thermoelectric cooling elements. The trough can be operated over a temperature range of 10-50°C. A simple feedback loop allows for measurement and control of the subphase temperature. The surface pressure is measured by a Wilhelmy plate-type transducer with a
filter-paper plate (R&K, Wiesbaden, Germany).
For fluorescence imaging, a Nikon Optiphot with the stage removed is
positioned above the trough. A 40× power long-working-distance objective designed for use with fluorescence systems is used. The
trough is mounted on a motorized xyz translation stage: the z axis is used for focusing and the x and
y axes are used to scan over different regions. A 100-watt
high-pressure mercury lamp was used for excitation. A dichroic
mirror/barrier filter assembly is used to direct the excitation light
onto the monolayer (with a normal angle of incidence) and to filter the
emitted fluorescence. The emitted fluorescence is collected by the
objective and detected via a Silicon Intensified Target (SIT) camera.
Images are recorded by a JVC super VHS VCR and digitized via a Scion
frame grabber. The resulting digitized images are processed and
analyzed following a custom-designed protocol (Lipp et al., 1997b
).
The monolayers were examined over a range of temperatures between 30 and 37°C; for these lipid and protein mixtures there was no
significant difference in isotherms or morphology over this temperature
range (Lipp et al., 1997a
; Takamoto, 1999
). Due to the increased
convection and leakage around the barriers at the higher temperature,
transfers for AFM were done primarily at 30°C (Lee et al., 1998
). All
isotherms presented are typical; each isotherm was repeated numerous
times to ensure reproducibility. Compressions were done
quasi-statically: the typical time for a compression-expansion cycle
was ~1 h. No variations of the isotherms were found for rates twice
as fast or as slow.
Selected monolayers were transferred to mica substrates for AFM using a
custom-built monolayer transfer system (Lee et al., 1998
). A modified
Nanoscope III FM (Digital Instruments, Santa Barbara, CA) was used for
imaging. A low-resolution fluorescence optical microscope was used to
position the AFM tip onto specific regions of the sample (Lee et al.,
1998
). Once the desired regions were located, AFM imaging was done with
a 150 µm × 150 µm (J) scanner in contact mode. Silicon
nitride tips with a spring constant of 0.12 N/m were used. Exerting
large forces on the sample was a concern during imaging, so samples
were checked often for deformation. This was done by imaging for a few
minutes on a smaller region (~20 µm), then zooming out to check
whether damage had been done to the scanned region.
Monolayer mechanical properties were measured using a custom-built
monolayer viscometer based on a design by Brooks et al. (1999)
. A
dual-barrier custom-built trough was equipped with parallel hydrophilic
glass plates spaced 1.5 cm apart to create a 10-cm-long flow cell
within the trough. A small magnetic needle (~1 cm long and 0.5 mm in
diameter) in a Teflon boat was floated on the air-water interface
between the two glass plates. A force was applied parallel to the long
axis of the needle by a magnetic field gradient created by a pair of
Helmholtz coils located on opposite sides of the trough. The magnitude
of the magnetic field gradient, and hence the force on the needle, is
proportional to the current in the coils. The needle position is
followed with a video camera to determine the velocity of the needle.
The needle rapidly comes to a steady velocity for a given force. The
velocity is proportional to the viscosity of the monolayer; high needle
velocities imply low monolayer viscosity, low needle velocities imply a
higher monolayer viscosity. As the monolayer is certainly
non-Newtonian, we cannot report a single viscosity, but rather just
compare the terminal velocities at a given applied force. The velocity
is normalized with respect to the needle velocity of the clean
subphase. Temperature control was not available for this trough, so all measurements were done at ~25°C. The needle sinks at sufficiently high surface pressure, so measurements are limited to <50 mN/m.
| |
RESULTS |
|---|
|
|
|---|
Fig. 1 A shows typical
cyclic isotherms (compression-expansion-compression) for the
DPPC/POPG/PA, 68:22:8 (wt/wt/wt) model lipid mixture on a buffered
saline subphase (150 mM NaCl, 5 mM CaCl, 0.2 mM NaHCO3, pH = 6.9)
at 30°C without protein. The surface pressure,
, is the difference between the bare water surface tension (~72
mN/m for saline at 30°C) and the measured surface tension,
:
= 72
. Hence, a high surface pressure corresponds to a low surface tension. While the lipid mixture achieves high surface
pressures, the second compression is shifted to lower area per molecule
due to the selective removal, or squeeze-out of the unsaturated POPG
(Lipp, 1997
; Takamoto, 1999
). By the second compression, most of the
POPG has been lost to the subphase irreversibly. The collapse pressure
of a monolayer is the highest surface pressure or lowest surface
tension attainable before the film fails. High and reproducible
collapse pressures are essential to minimizing the work of breathing.
However, for the lipids alone, on repeated compression, the collapse
pressure steadily decreased.
|
Fig. 1 B shows the change in the isotherm on addition of 2 wt % SP-Cff peptide (Davis et al., 1998
) to the
DPPC/POPG/PA, 68:22:8 (wt/wt/wt) lipid mixture at 30°C. For the
second and subsequent compressions, the peptide induces a break in the
isotherm at a surface pressure of ~50 mN/m and the offset in
molecular area is reduced, especially at high surface pressure. The
protein helps retain the unsaturated lipid components in the surface
film. The maximum surface pressure increases to ~70 mN/m on the
second and subsequent compressions. For these lipid and protein
mixtures there was no significant difference in isotherms or morphology over the temperature range of 30-37°C. (Lipp et al., 1997a
;
Takamoto, 1999
).
Contact mode AFM images of the SP-Cff containing monolayers
show the change in morphology at surface pressures above and below the
break in the isotherm. Fig. 2
A shows coexisting solid (light gray) and fluid
(dark gray) phase domains in a
DPPC/POPG/PA/SP-Cff, 68:22:8:2 (wt/wt/wt/wt) monolayer
transferred at a surface pressure of 45 mN/m at 30°C (Lee et al.,
1998
). The domain sizes and shapes are consistent with fluorescence
images at the air-water interface before transfer (von Nahmen et al.,
1997
; Takamoto, 1999
). The solid phase is made up
primarily of DPPC and PA (Lipp, 1997
), and the fluid phase is primarily
POPG and protein (Lipp et al., 1998
; von Nahmen et al., 1997
). The
height trace shows that the fluid phase is 1-2 nm lower than the solid
phase. This difference is due to the combination of the greater
thickness of the solid phase monolayer relative to the fluid phase
monolayer, and the greater compressibility of the fluid phase (Marsh,
1990
).
|
Fig. 2 B shows an AFM image of the same film transferred at
a surface pressure of 55 mN/m and 30°C, above the break in the isotherm. The fluid phase domains (light gray) are 4 nm
higher than the solid phase (dark gray). This shows that the
fluid phase has increased in thickness by 5-6 nm in comparison to Fig.
2 A, which is roughly equal to a bilayer of POPG (Marsh,
1990
). The addition of SP-Cff to the lipid mixture induced a
two- to three-dimensional phase transition. Instead of being
squeezed-out, the unsaturated lipid remains at the interface, although
in a multilayer, rather than a monolayer, form. Without the protein,
the fluid phase is almost completely removed from the interface
(Takamoto, 1999
).
DPPC/POPC (palmitoyloleoylphosphatidylcholine), DPPC/PA/POPC, DPPG
(dipalmitoylphosphatidylglycerol)/POPG (Takamoto, 1999
), and DPPC/DPPG
(von Nahmen et al., 1997
) lipid mixtures showed similar transitions in
the presence of native human recombinant SP-C (von Nahmen et al., 1997
)
or SP-Cff (Takamoto, 1999
). SP-C and SP-Cff
contain a hydrophobic
-helix segment that is capable of spanning a
lipid bilayer (Johansson, 1998
). At ~50 mN/m surface pressure, the
orientation of SP-C likely switches from parallel to perpendicular to
the interface, allowing SP-C to bridge the thickened fluid lipids
(Gericke et al., 1997
; von Nahmen et al., 1997
). The thicker fluid
phase allows the surface pressure to be distributed over a wider cross
section; hence, the absolute force on the fluid domain is smaller than
that required to squeeze the lipids out of the interface. On expansion,
these thickened patches quickly reincorporate into the monolayer at
surface pressures below ~45 mN/m.
Surprisingly, the fluid phase transition depends on the properties of
the solid phase. Fig. 1 C shows the isotherm of a 3:1 DPPC/POPC lipid mixture with 2 wt % SP-Cff at 30°C.
Instead of the small break in the isotherm at ~50 mN/m (Fig. 1
B), there is a distinct plateau at a pressure of 40 mN/m,
and another break in the isotherm at ~55 mN/m on the second
compression. Fig. 2 C shows an AFM image above the first
plateau in the isotherm at 50 mN/m. With no PA in the solid phase, the
fluid phase forms multilayer steps rather than uniformly thickening
(Fig. 2 B). This is the same behavior as observed earlier
for 3:1 DPPC/DPPG mixtures with human recombinant SP-C (von Nahmen et
al., 1997
); hence it appears that the palmitoylated cysteines are not
essential for this transition (see sequence information in Materials
and Methods). When PA is added to DPPC monolayers, the molecular tilt decreases, increasing the thickness of the monolayer; the molecular ordering becomes longer-ranged, and the temperature range of the solid
phase increases (Lipp, 1997
; Lee, Majewski, von Nahmen, Gopal, Howes,
Kjaer, Smith and Zasadzinski, submitted for publication). These changes
likely lead to changes in the mechanical properties of the monolayer.
This may explain the benefits obtained by supplementing bovine lung
surfactant extract with palmitic acid in the clinically used Survanta.
However, the PA fraction in native surfactants extracted by lavage is
typically lower and ranges from 0 to 3 wt % (Batenburg and Haagsman,
1998
), so the role of PA in natural surfactants is less clear.
To measure monolayer mechanical properties, we have designed and built
a magnetic needle monolayer viscometer (Brooks et al., 1999
). The basic
principle is that a small magnet supported in a Teflon "boat"
floating on the monolayer surface is subjected to a constant force
using a controlled magnetic field gradient in the plane of the
monolayer and oriented along the axis of the "boat." Higher needle
velocities correspond to low monolayer viscosity and low needle
velocities with high viscosity for a given magnetic force. The velocity
is normalized to the speed of the needle on a clean subphase. Fig.
3 shows the normalized needle velocity for a given applied magnetic force for a monolayer of 77 wt % DPPC and
23 wt % POPG with varied PA fractions on a pure water subphase at
25°C. With no PA in the monolayer, the needle velocity is constant
for all surface pressures and is nearly the same as for a clean
interface with no surfactant (normalized speed of 1). For 10 wt % PA,
we see a dramatic decrease in needle velocity at surface pressures from
35 to 40 mN/m, which corresponds to a large increase in viscosity. This
PA-induced change in the monolayer rigidity at high surface pressure
correlates with the changes in monolayer morphologies between Fig. 2,
B and C. The optimal PA content suggested by
Tanaka (Tanaka et al., 1986
) in developing Survanta is ~10% by
weight. At this PA fraction, there is a high viscosity at high surface
pressure, but low viscosity at low surface pressure. This PA fraction
also corresponds to changes in the tendency of the monolayer to fold
rather than fracture at collapse (Takamoto, 1999
). A high viscosity at
high surface pressure appears to be necessary for the morphological
transitions shown in Fig. 2, but a low viscosity at low surface
pressures may be necessary for good monolayer respreading. At 20 wt % PA, the needle velocity begins to decrease on initial compression; by a
surface pressure of ~20 mN/m, the film is so rigid that the needle
cannot move with the maximum force we can apply.
|
The net result of adding ~10 wt % PA to the monolayer is that the
surface pressure is higher for a given compression with PA than without
PA (See Fig. 1, B and C; compare small break in the isotherm in 1 B with the distinct plateau in 1 C), and the uniformly thickened fluid phase (Fig. 2
B) likely reincorporates more efficiently into the monolayer
on expansion than does the step-wise thickened fluid phase without PA
(Fig. 2 C). This explains one of the benefits derived from
supplementing bovine lung surfactant extract with PA in the production
of Survanta. Hexadecanol can be substituted for PA and produces similar
effects on DPPC packing in the solid phase, and on isotherms and
monolayer morphology (Takamoto, 1999
). This helps explains the role of
hexadecanol in Exosurf, another clinically used replacement surfactant
(Poulain and Clements, 1995
).
The consistent behavior of SP-C with the wide variety of solid and
fluid phase lipids suggests that a similar transition should occur in
the more chemically complex bovine lung surfactant extract, Survanta.
Fig. 1 D shows cyclic isotherms for Survanta at 37°C, which was deposited from the aqueous suspension directly onto the
subphase. The isotherm was similar to the model lipid/SPCff mixture shown in Fig. 1 B. On the second and subsequent
compressions, a small break in the isotherm was present at 45-50 mN/m,
just as in the model mixture (Fig. 1 B). AFM images of films
transferred (Lee et al., 1998
) at 45 mN/m (Fig. 2 D) and at
55 mN/m (Fig. 2 E) at 30°C showed the same transitions as
the model mixture. In Fig. 2 D, below the break in the
isotherm, the solid phase domains (light gray) are 1-2 nm
thicker than the fluid domains (dark gray), similar to Fig.
2 A. The small white spots are lipid aggregates trapped
during the transfer from the air-water interface to the substrate. Fig.
2 E shows the film transferred at 55 mN/m, above the break
in the isotherm. As in Fig. 2 B, the fluid phase domains are
uniformly thicker by 1-2 nm than the solid phase, indicating that the
native SP-C in Survanta induces a similar morphological change as
SP-Cff or the human recombinant SP-C (von Nahmen et al.,
1997
). The change in thickness is not as great as in the model
mixtures, and is not consistent with the thickness of the typical
bilayer thickness of ~5 nm. This may be due to the smaller SP-C
fraction in Survanta than in the model mixtures or in native surfactant
(Walther et al., 1998
; Mizuno et al., 1995
), the lack of palmitoylation
in the SP-Cff used in the model mixtures, or to difficulties
in transfer for AFM of the more complex mixtures. Higher
SP-Cff fractions likely led to a proportionately greater
change in the fluid phase thickness in the model mixtures (Takamoto,
1999
). The uniform change in thickness of the fluid phase domains is
likely due to the PA added to Survanta. SP-B can also lead to the
formation of a monolayer to multilayer transition in the fluid phase
lipids (Krol et al., 2000
; Lipp et al., 1998
). Mixture of native SP-B
and SP-C with phosphatidylcholines show a similar thickening transition
by AFM (Grunder et al., 1999
), although the morphology of the
multilayer patches is less well defined and smaller with SP-B than with
SP-C (Krol et al., 2000
; Lipp et al., 1998
).
While SP-C is responsible for helping maintain the fluid lipids in the
vicinity of the air-water interface, the SP-B protein modifies
monolayer collapse, thereby ensuring reproducibly low surface tensions
(Lipp et al., 1998
). Fig. 4 A
shows a fluorescence microscopy image of a 67:22:8:3 (wt/wt/wt/wt)
DPPC/POPG/PA/full length SP-B1-78 with 0.5 mol
% of the fluorescent probe NBD-PG at the collapse pressure of 65 mN/m
at 37°C. The monolayer undergoes a
three-dimensional buckling into the subphase (bright area in
center of image), but maintains the monolayer morphology of solid
phase domains (dark) in a continuous fluid phase
(bright) not only at the interface, but throughout the
folded region. There is no loss of material to the subphase on
collapse. The buckled areas reincorporate into the monolayer on
expansion over a range of surface pressures from the collapse pressure
to ~10 mN/m.
|
Fig. 4 B shows a fluorescence image of Survanta at its
collapse pressure at 37°C. The bright streak is a fracture in the
monolayer. These fractures are similar to those in pure DPPC monolayers
(Lipp, 1997
) at collapse, and lead to inefficient respreading. The
monolayer exhibits the similar bright-dark, solid-fluid coexistence as
the model mixture, although the domain sizes are smaller. It is
estimated that the amount of SP-B in Survanta is only ~0.1 wt % (Walther et al., 1997
; Taeusch et al., 1986
), while the amount of SP-B in native surfactant is closer to 1.5-2 wt % (Mizuno et al., 1995
). However, the exact amount of SP-B, SP-C, or lipid in any native surfactant or surfactant extract has not been accurately measured because reliable methods of harvesting surfactant from the alveoli are
not available (Mizuno et al., 1995
). When 5 wt % SP-B1-25 is added to the Survanta suspension,
collapse occurs via buckling (Fig. 4 C), just as in the
model mixture with protein (Fig. 4 A). The folded regions of
the monolayer have similar morphology, and likely composition, to the
rest of the monolayer. The folded material rapidly reincorporates into
the monolayer on expansion, again over a range of surface pressure from
collapse to ~15 mN/m. Fig. 1 E shows the cycling isotherms
of Survanta with 5 wt % added SP-B1-25 peptide
at collapse at 37°C. The isotherm is quite similar to that in Fig. 1
D. The peptide partitions mainly into the fluid phase
domains and does not affect the solid phase domains to any great
extent. From these and earlier results (Lipp et al., 1998
), the folding
transition is relatively independent of the details of the lipid
composition of the monolayer. There is also a minimum fraction of SP-B
required in the monolayer to induce the monolayer folding transition. A
minimum fraction of SP-B is also necessary for optimal surfactant
performance in vivo. Adding native SP-B (Mizuno et al., 1995
) or
SP-B1-25 peptide (Walther et al., 1997
) to
Survanta improves oxygenation and other measures of surfactant
performance in animals. Antibodies to SP-B or a genetic deficiency of
SP-B causes respiratory failure (Robertson and Halliday, 1998
; Tokieda
et al., 1997
).
Correlating morphological and isotherm measurements of Langmuir
monolayers to the organization and mechanics of the surfactant within
the alveoli during normal breathing is much more problematic. The
maximum static surface tension within excised rabbit lungs was measured
to be ~30 mN/M (surface pressure of ~40 mN/m) (Bachofen et al.,
1987
), while the minimum surface tension has been estimated to be close
to zero (Bachofen et al., 1987
; Schürch et al., 1976
, 1978
). No
measurements have been done of the dynamic surface tension during the
normal respiratory cycle, so the range of surface tensions during
actual breathing is unknown. The maximum surface tension (minimum
surface pressure) on a Langmuir trough depends on the mode of
deposition of surfactant and the concentration, if any, of surfactant
in the subphase, but can range from 40 (Schürch et al., 1976
,
1978
) to 70 mN/m (surface pressures of 30-0 mN/m). In our experiments,
the surface pressure was forced to cycle between zero and the collapse
pressure of the particular surfactant mixture by varying the surface
area; it is unclear if either the maximum or minimum surface pressure
shown in the isotherms are reached during breathing. However, both of
the prominent morphological transitions we have observed
the
multilayer formation induced by SP-C in the fluid phase domains and the
folding transition at collapse induced by SP-B
occur at surface
pressures between 40 and 70 mN/m on compression, which shows that these
are within the range of measured maximum and minimum surface tensions
in static lungs.
The change in surface area of the lungs during breathing is an
important corollary to the range of surface tension during breathing.
When lung volume changes from 40 to 100% of total lung capacity, the
lung epithelial cell basal surface area increases 35% (Tschumperlin
and Margulies, 1999
). However, the actual area change of the air-fluid
interface is more difficult to measure (Wirtz and Dobbs, 2000
).
Secretion of surfactant from the type II cell is postulated to be
induced by deep sighing breaths and the resulting large increases in
the lung volume and surface area (Wirtz and Dobbs, 2000
). The change in
relative area in Langmuir isotherms is arbitrary; the monolayer area is
changed sufficiently so that the entire range between the collapse
pressure and zero surface pressure is recorded. The relative change in
surface pressure for a given change in area is typically much greater
on expansion than on compression of the monolayer (see Fig. 1),
especially at high surface pressures after monolayer collapse. Hence, a
given change in area could result in a much larger change in surface pressure depending on the history of the monolayer. The folds in the
collapsed monolayer (Fig. 4) or the multilayers in the fluid domains
(Fig. 2) revert back to the monolayer over a range of surface pressures
from the collapse pressure to as low as 15 mN/m. It is unclear if the
change in surface area during normal breathing would cause these
structures to occur or disappear on each breathing cycle.
| |
CONCLUSIONS |
|---|
|
|
|---|
Although the clinical importance of the LS proteins SP-B and SP-C
is well established (Tanaka et al., 1986
; Poulain and Clements, 1995
;
Hawgood et al., 1998
; Goerke, 1998
; Johansson, 1998
), the role of these
proteins in altering the properties of surfactant monolayers remains
ambiguous. It is also relatively well established that the fatty acid
and unsaturated lipid components of lung surfactant are important to
the proper function of surfactant at all stages of the compression and
expansion cycle (Veldhuizen et al., 1998
), although the exact fraction
of any lipid in lung surfactants is still not well established. Direct
imaging with fluorescence and atomic force microscopy clearly show that
the interactions between SP-B, SP-C, and palmitic acid with the
remaining lipid components of synthetic and animal extract surfactants
are non-ideal and lead to novel morphologies likely to be important to
LS function. Establishing the properties of SP-B, SP-C, and PA are
essential to determining the composition of an effective synthetic
surfactant and in evaluating synthetic peptide function.
SP-C retains a continuous fluid phase network of unsaturated lipids and
proteins, separating islands of solid phase lipids up to monolayer
collapse. The nature of the fluid phase transition depends on the lipid
composition: when PA is present in the monolayer, the fluid phase
thickens uniformly, while without PA, the fluid phase forms multilayer
stacks. Native SP-C, palmitoylated, human recombinant SP-C (von Nahmen
et al., 1997
), and SP-Cff appear to have very similar
effects on the monolayer.
With SP-B, collapse occurs by a reversible buckling in which the monolayer is flexible enough to fold, while retaining sufficient cohesion to prevent loss of material to the subphase. The folds have the same composition as the monolayer, and reversibly reincorporate into the monolayer on expansion. Both the full length protein, SP-B1-78, and the SP-B1-25 peptide are capable of inducing this folding transition.
PA, when added to DPPC monolayers, increases the monolayer viscosity at high surface pressures, but not at low surface pressure. This increased monolayer rigidity at high surface pressures appears to be necessary to allow homogeneous multilayer formation in the fluid phase via SP-C and the folding collapse mechanism in films also containing SP-B. Higher fractions of PA likely make the monolayer too rigid to respread.
These two- to three-dimensional transitions allow collapse to occur at elevated surface pressures while making it possible for the protein and unsaturated lipid components to remain associated with the monolayer, facilitating rapid respreading. Without the proteins, the fluid phase lipids are squeezed-out from the monolayer, leaving behind a rigid DPPC-rich monolayer that fractures irreversibly at collapse. These morphological transitions of multilayer formation, followed by a folding and unzipping process, explains how lung surfactant can both achieve low surface tensions and respread readily from the collapsed state, without the need to undergo any compositional refinement upon compression. The presence of the protein-containing folds extending into the subphase at high compression may also provide a mechanism for incorporation of new material to the interface upon expansion. A thorough understanding of the roles of the lipids and proteins in lung surfactant can provide a mechanism-based rationale for the design of replacement surfactants for treatment of respiratory distress syndrome.
| |
ACKNOWLEDGMENTS |
|---|
J.D., K.Y.C.L., M.M.L., and J.A.Z. were supported by National Institutes of Health Grant HL-51177; J.A.Z. and A.J.W. were also supported by the Tobacco Related Disease Research Program Grant 8RT-0077. J.D. was supported by Tobacco Related Disease Research Program Grant 8DT-0171. A.J.W. was also supported by National Institutes of Health Grant HL55534, the Drew RCMI Bioinformatics Core (NCRR/RCMI G12 RR 03026), and National Institutes of Health Small Equipment Grant GM 50483. K.Y.C.L. was supported by the March of Dimes Award (5-FY98-0728), the Searle Scholars Program/The Chicago Community Trust (99-C-105), the American Lung Association (RG-085-N), and the Packard Foundation (99-1465).
| |
FOOTNOTES |
|---|
Received for publication 10 March 2000 and in final form 12 February 2001.
Address reprint requests to Joseph A. Zasadzinski, Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106-5080. Tel.: 805-893-4769; Fax: 805-893-4731; E-mail: gorilla{at}engineering.ucsb.edu.
| |
REFERENCES |
|---|
|
|
|---|
Biophys J, May 2001, p. 2262-2272, Vol. 80, No. 5
© 2001 by the Biophysical Society 0006-3495/01/05/2262/11 $2.00
This article has been cited by other articles:
![]() |
Y. Y. Zuo, E. Keating, L. Zhao, S. M. Tadayyon, R. A. W. Veldhuizen, N. O. Petersen, and F. Possmayer Atomic Force Microscopy Studies of Functional and Dysfunctional Pulmonary Surfactant Films. I. Micro- and Nanostructures of Functional Pulmonary Surfactant Films and the Effect of SP-A Biophys. J., May 1, 2008; 94(9): 3549 - 3564. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lhert, W. Yan, S. C. Biswas, and S. B. Hall Effects of Hydrophobic Surfactant Proteins on Collapse of Pulmonary Surfactant Monolayers Biophys. J., December 15, 2007; 93(12): 4237 - 4243. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Stenger and J. A. Zasadzinski Enhanced Surfactant Adsorption via Polymer Depletion Forces: A Simple Model for Reversing Surfactant Inhibition in Acute Respiratory Distress Syndrome Biophys. J., January 1, 2007; 92(1): 3 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gerber, M. P. Krafft, T. F. Vandamme, M. Goldmann, and P. Fontaine Fluidization of a Dipalmitoyl Phosphatidylcholine Monolayer by Fluorocarbon Gases: Potential Use in Lung Surfactant Therapy Biophys. J., May 1, 2006; 90(9): 3184 - 3192. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Taeusch, J. B. de la Serna, J. Perez-Gil, C. Alonso, and J. A. Zasadzinski Inactivation of Pulmonary Surfactant Due to Serum-Inhibited Adsorption and Reversal by Hydrophilic Polymers: Experimental Biophys. J., September 1, 2005; 89(3): 1769 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Zasadzinski, T. F. Alig, C. Alonso, J. B. de la Serna, J. Perez-Gil, and H. W. Taeusch Inhibition of Pulmonary Surfactant Adsorption by Serum and the Mechanisms of Reversal by Hydrophilic Polymers: Theory Biophys. J., September 1, 2005; 89(3): 1621 - 1629. [Abstract] [Full Text] [PDF] |
||||